Matches in SemOpenAlex for { <https://semopenalex.org/work/W2913231661> ?p ?o ?g. }
- W2913231661 endingPage "1065" @default.
- W2913231661 startingPage "1047" @default.
- W2913231661 abstract "Background: Platinum (II) (Pt(II))-based anticancer drugs dominate the chemotherapy field of ovarian cancer. However, the patient's quality of life has severely limited owing to dose-limiting toxicities and the advanced disease at the time of diagnosis. Multifunctional tumor-targeted nanosized ultrasound contrast agents (glutathione (GSH)-sensitive platinum (IV) (Pt(IV)) prodrug-loaded phase-transitional nanoparticles, Pt(IV) NP-cRGD) were developed for precise theranostics against ovarian cancer. Methods: Pt(IV) NP-cRGD were composed of a perfluorohexane (PFH) liquid core, a hybrid lipid-polymer shell with PLGA12k-PEG2k and DSPE-PEG1k-Pt(IV), and an active targeting ligand, the cRGD peptide (PLGA: poly(lactic-co-glycolic acid), PEG: polyethylene glycol, DSPE: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, cRGD: cyclic Arg-Gly-Asp). Pt(IV), a popular alternative to Pt(II), was covalently attached to DSPE-PEG1k to form the prodrug, which fine-tuned lipophilicity and improved cellular uptake. The potential of Pt(IV) NP-cRGD as contrast agents for ultrasound (US) imaging was assessed in vitro and in vivo. Moreover, studies on the antitumor efficiency and antitumor mechanism of Pt(IV) NP-cRGD assisted by US were carried out. Results: Pt(IV) NP-cRGD exhibited strong echogenic signals and excellent echo persistence under an US field. In addition, the GSH-sensitive and US-triggered drug delivery system maximized the therapeutic effect while reducing the toxicity of chemotherapy. The mechanistic studies confirmed that Pt(IV) NP-cRGD with US consumed GSH and enhanced reactive oxy gen species (ROS) levels, which further causes mitochondria-mediated apoptosis. Conclusion: A multifunctional nanoplatform based on phase-transitional Pt(IV) NP-cRGD with US exhibited excellent echogenic signals, brilliant therapeutic efficacy and limited side effect, suggesting precise theranostics against ovarian cancer." @default.
- W2913231661 created "2019-02-21" @default.
- W2913231661 creator A5017054801 @default.
- W2913231661 creator A5031610986 @default.
- W2913231661 creator A5035085963 @default.
- W2913231661 creator A5064398610 @default.
- W2913231661 creator A5066874159 @default.
- W2913231661 creator A5076935876 @default.
- W2913231661 creator A5077185189 @default.
- W2913231661 creator A5077863311 @default.
- W2913231661 creator A5089199336 @default.
- W2913231661 date "2019-01-01" @default.
- W2913231661 modified "2023-10-12" @default.
- W2913231661 title "GSH-sensitive Pt(IV) prodrug-loaded phase-transitional nanoparticles with a hybrid lipid-polymer shell for precise theranostics against ovarian cancer" @default.
- W2913231661 cites W1678884887 @default.
- W2913231661 cites W1998327928 @default.
- W2913231661 cites W2000899361 @default.
- W2913231661 cites W2001257757 @default.
- W2913231661 cites W2003392370 @default.
- W2913231661 cites W2027901828 @default.
- W2913231661 cites W2030018261 @default.
- W2913231661 cites W2030964111 @default.
- W2913231661 cites W2053026677 @default.
- W2913231661 cites W2079485418 @default.
- W2913231661 cites W2081986311 @default.
- W2913231661 cites W2088787228 @default.
- W2913231661 cites W2091945030 @default.
- W2913231661 cites W2142462836 @default.
- W2913231661 cites W2153089700 @default.
- W2913231661 cites W2208841952 @default.
- W2913231661 cites W2249076626 @default.
- W2913231661 cites W2282989227 @default.
- W2913231661 cites W2310351445 @default.
- W2913231661 cites W2317079887 @default.
- W2913231661 cites W2343683610 @default.
- W2913231661 cites W2346576309 @default.
- W2913231661 cites W2401118467 @default.
- W2913231661 cites W2401262504 @default.
- W2913231661 cites W2478264687 @default.
- W2913231661 cites W2510382221 @default.
- W2913231661 cites W2549345277 @default.
- W2913231661 cites W2583207915 @default.
- W2913231661 cites W2589430454 @default.
- W2913231661 cites W2594404528 @default.
- W2913231661 cites W2741643215 @default.
- W2913231661 cites W2742914980 @default.
- W2913231661 cites W2752212449 @default.
- W2913231661 cites W2766010926 @default.
- W2913231661 cites W2768549821 @default.
- W2913231661 cites W2771025239 @default.
- W2913231661 cites W2772735971 @default.
- W2913231661 cites W2773329344 @default.
- W2913231661 cites W2781525129 @default.
- W2913231661 cites W2790642385 @default.
- W2913231661 cites W2791935253 @default.
- W2913231661 cites W2792975649 @default.
- W2913231661 cites W2799938265 @default.
- W2913231661 cites W2803554610 @default.
- W2913231661 cites W2808612002 @default.
- W2913231661 cites W2867022353 @default.
- W2913231661 cites W2883635852 @default.
- W2913231661 cites W596075202 @default.
- W2913231661 doi "https://doi.org/10.7150/thno.29820" @default.
- W2913231661 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6401401" @default.
- W2913231661 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30867815" @default.
- W2913231661 hasPublicationYear "2019" @default.
- W2913231661 type Work @default.
- W2913231661 sameAs 2913231661 @default.
- W2913231661 citedByCount "56" @default.
- W2913231661 countsByYear W29132316612019 @default.
- W2913231661 countsByYear W29132316612020 @default.
- W2913231661 countsByYear W29132316612021 @default.
- W2913231661 countsByYear W29132316612022 @default.
- W2913231661 countsByYear W29132316612023 @default.
- W2913231661 crossrefType "journal-article" @default.
- W2913231661 hasAuthorship W2913231661A5017054801 @default.
- W2913231661 hasAuthorship W2913231661A5031610986 @default.
- W2913231661 hasAuthorship W2913231661A5035085963 @default.
- W2913231661 hasAuthorship W2913231661A5064398610 @default.
- W2913231661 hasAuthorship W2913231661A5066874159 @default.
- W2913231661 hasAuthorship W2913231661A5076935876 @default.
- W2913231661 hasAuthorship W2913231661A5077185189 @default.
- W2913231661 hasAuthorship W2913231661A5077863311 @default.
- W2913231661 hasAuthorship W2913231661A5089199336 @default.
- W2913231661 hasBestOaLocation W29132316611 @default.
- W2913231661 hasConcept C108215921 @default.
- W2913231661 hasConcept C121608353 @default.
- W2913231661 hasConcept C12554922 @default.
- W2913231661 hasConcept C126322002 @default.
- W2913231661 hasConcept C150903083 @default.
- W2913231661 hasConcept C178790620 @default.
- W2913231661 hasConcept C181199279 @default.
- W2913231661 hasConcept C185592680 @default.
- W2913231661 hasConcept C201399114 @default.
- W2913231661 hasConcept C202751555 @default.
- W2913231661 hasConcept C207001950 @default.
- W2913231661 hasConcept C21951064 @default.
- W2913231661 hasConcept C2776964284 @default.